1 |
Imran M, Amjad A, Haidri FR. Frequency of hospital acquired pneumonia and its microbiological etiology in medical intensive care unit[J]. Pak J Med Sci, 2016, 32(4): 823-826.
|
2 |
Agrafiotis M, Siempos II, Ntaidou TK, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis[J]. Int J Tuberc Lung Dis, 2011, 15(9): 1154-1163, i-v.
|
3 |
Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator-associated pneumonia in a large matched cohort[J]. Infect Control Hosp Epidemiol, 2012, 33(3): 250-256.
|
4 |
张玉江,张 巧,任之栋,等. PSI、APACHEⅡ和SOFA三种评分对医院获得性肺炎预后的评估价值[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(3): 285-288
|
5 |
许 静,陈 炜,张 鸿,等. 医院获得性肺炎的治疗及预防进展[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(1): 123-126.
|
6 |
Tsay TB, Jiang YZ, Hsu CM, et al. Pseudomonas aeruginosa colonization enhances ventilator-associated pneumonia-induced lung injury[J]. Respir Res, 2016, 17(1): 101.
|
7 |
Ramphal R, Balloy V, Jyot J, et al. Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin[J]. J Immunol, 2008, 181(1): 586-592.
|
8 |
El Solh AA, Alhajhusain A. Update on the treatment of pseudomonas aeruginosa pneumonia[J]. J Antimicrob Chemother, 2009, 64(2): 229-238.
|
9 |
Jacqueline C, Roquilly A, Desessard C, et al. Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response[J]. J Antimicrob Chemother, 2013, 68(1): 177-183.
|
10 |
Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of pseudomonas aeruginosa infections[J]. Drugs, 2007, 67(3): 351-368.
|
11 |
Li J, Zou M, Dou Q, et al. Characterization of clinical extensively drug-resistant Pseudomonas aeruginosa in the Hunan province of China[J]. Ann Clin Microbiol Antimicrob, 2016, 15(1): 35.
|
12 |
Ren Q, Zhao S, Ren C, et al. Astragalus polysaccharide alleviates LPS-induced inflammation injury by regulating miR-127 in H9c2 cardiomyoblasts[J]. Int J Immunopathol Pharmacol, 2018, 32: 2058738418759180.
|
13 |
Lu J, Chen X, Zhang Y, et al. Astragalus polysaccharide induces anti-inflammatory effects dependent on AMPK activity in palmitate-treated RAW264.7 cells[J]. Int J Mol Med, 2013, 31(6): 1463-1470.
|
14 |
Wang X, Li Y, Yang X, et al. Astragalus polysaccharide reduces inflammatory response by decreasing permeability of LPS-infected Caco2 cells[J]. Int J Biol Macromol, 2013, 61: 347-352.
|
15 |
Wang XH, Huang WM. Astragalus polysaccharides exert protective effects in newborn rats with bronchopulmonary dysplasia by upregulating the expression of EGFL7 in lung tissue[J]. Int J Mol Med, 2014, 34(6): 1529-1536.
|
16 |
Liu QY, Yao YM, Zhang SW, et al. Astragalus polysaccharides regulate T cell-mediated immunity via CD11c(high)CD45RB(low) DCs in vitro[J]. J Ethnopharmacol, 2011, 136(3): 457-464.
|
17 |
Yuan LB, Hua CY, Gao S, et al. Astragalus polysaccharides attenuate monocrotaline-induced pulmonary arterial hypertension in rats[J]. Am J Chin Med, 2017, 45(4): 773-789.
|
18 |
Cai S, Li Y, Wang K, et al. Pathogenic Effects of biofilm on pseudomonas aeruginosa pulmonary infection and its relationship to cytokines[J]. Med Sci Monit, 2016, 22: 4869-4874.
|
19 |
Wang Q, Ma L, Liu T, et al. TIPE2 suppresses pseudomonas aeruginosa keratitis by inhibiting NF-κB signaling and the infiltration of inflammatory cells[J]. J Infect Dis, 2019, 220(6): 1008-1018.
|
20 |
Tak PP, Firestein GS. NF-kappa B: a key role in inflammatory diseases[J]. J Clin Invest, 2001, 107(1): 7-11.
|